CJC-1295 DAC Side Effects

Due to their varied biological functions, peptides are becoming increasingly significant in scientific research. An increasingly prominent peptide is CJC-1295 DAC (Drug Affinity Complex), a growth hormone-releasing hormone (GHRH) synthetic analog.

Scientists are most interested in CJC-1295 DAC because it may potentially improve growth hormone (GH) levels by prolonging the action of natural GHRH in the body. Beyond its application in hormonal cascades, recent research has suggested that CJC-1295 DAC may have broader implications for other physiological systems' functioning, and it offers new options for scientific investigation and exploration.

What is CJC-1295 DAC?

CJC-1295 DAC is a GHRH (growth hormone-releasing hormone) analog with improved pharmacokinetic properties. By adding a Drug Affinity Complex (DAC), the timeframe in which the peptide acts in the body can be extended, and it may also be able to sustain a long-lasting release of endogenous growth hormone (GH).

The defining characteristic of this peptide, among other GHRH analogs, is that it reportedly possesses a longer half-life. This characteristic has drawn some spotlight in early investigations, especially studies that have studied its potential effect on growth, metabolic function, and cellular regeneration

How CJC-1295 DAC Works

Current research suggests that CJC-1295 DAC may function by binding to GHRH receptors in the pituitary gland. It is thought that this could potentially stimulate endogenous GH production and release. The DAC part binds to albumin in the bloodstream, slows the rate at which the kidneys clear it out—essentially increasing the window that the compound can remain active in the system.

Tests in the laboratory have indicated that keeping CJC-1295 in the system for an extended period can lead to more stable GH release. This increased activity can provide valuable information regarding the regulation of GH over time as well as its effect on various functions of the body.

Side Effects

While most people find CJC-1295 with DAC to be well tolerated, some side effects have been reported. More common side effects are described below:

Mild Water Retention

Some experience fluid retention as swelling or puffiness. This is usually temporary and disappears on its own.

Tingling or Numbness (Related to IGF-1)

Increased insulin-like growth factor 1 (IGF-1) levels can sometimes lead to excessive numbness or tingling, particularly the hands or feet.

Dizziness or Headaches

Hormonal changes can bring about mild dizziness or headaches, particularly during the initial adjustment period. These symptoms are generally temporary.

Flu-like Symptoms

A small cohort of patients become ill, similar to a low-grade cold or flu. Such symptoms may involve fatigue, overall body aches, or low-grade fever, but are infrequent.

Injection Site Reactions

Redness, slight irritation, or tenderness at the injection site can be observed. These reactions are usually minor and resolve quickly with proper injection technique.

Important Note Regarding Long-Term Use

Although long-term use of CJC-1295 is generally considered safe, especially when not combined with other growth hormones, caution is still best practiced. The benefit in this case is that this peptide rarely inhibits the body's natural production of growth hormones, so it is a more suitable option for long-term use.

Caution For Taking CJC-1295 with DAC

Although CJC-1295 with DAC is generally well tolerated when taken as directed, there are certain groups of individuals who should not take it at all, or take it only under strict medical supervision:

Individuals with a History of Cancer

As CJC-1295 is known to cause the release of growth hormone (GH) and IGF-1—both involved in cellular repair and regeneration, there is a fear that it may hasten the growth of any tumors that may be present, especially those sensitive to hormones. Anyone with a history of cancer or undergoing treatment for cancer should consult their doctor before using.

Diabetics or Blood Sugar Issues

IGF-1 has the ability to affect glucose metabolism in the body. In type 2 or type 1 diabetic or insulin-resistant people, this will result in varying blood glucose levels. For them, glucose must be monitored carefully. The majority of health professionals do not recommend taking this substance under the advice of a physician.

People with Heart or Circulatory Diseases

Increased GH and IGF-1 levels can potentially affect blood pressure, heart rate, and water retention. Individuals with a history of heart disease, high blood pressure, or stroke must consult a doctor before using CJC-1295.

Pregnant or Breastfeeding Women

CJC-1295 has not been well studied in pregnant or lactating women. Because it affects hormone levels, it could affect both the baby and the mother. As a precaution, it is best to avoid using this peptide while pregnant and breastfeeding.

Safety

Patients who tested this peptide noted it had minimal side effects. While particular groups should avoid using CJC-1295 DAC, it hasn't shown any serious side effects with the rest of the test subjects, making it safe for use.
However, before trying any new drug, you should consult your healthcare provider to make sure you are doing the right thing.

References:

1. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006 Dec;91(12):4792-7. doi: 10.1210/jc.2006-1702. Epub 2006 Oct 3. PMID: 17018654.
2. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JG. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006 Mar;91(3):799-805. doi: 10.1210/jc.2005-1536. Epub 2005 Dec 13. PMID: 16352683.
3. Bowers CY. Growth hormone-releasing peptides and growth hormone secretagogues: classification and functions. Pituitary. 1998;1(1):39-44. doi: 10.1023/a:1009965805796. PMID: 11757564.
4. Walker RF. Clinical applications of growth hormone secretagogues in aging and obesity. Horm Res. 2007;68 Suppl 5:72-6. doi: 10.1159/000114838. PMID: 18196961.
5. Ghigo E, Arvat E, Muccioli G, Camanni F. Growth hormone-releasing peptides. Eur J Endocrinol. 1997 Apr;136(4):445-60. doi: 10.1530/eje.0.1360445. PMID: 9135151.
6. Van der Lely AJ, Lamberts SW. Growth hormone-releasing hormone and its analogs: therapeutic applications and safety considerations. Drugs. 1997 Jul;54(1):1-10. doi: 10.2165/00003495-199754010-00001. PMID: 9225111.
7. Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006 Dec;291(6):E1290-4. doi: 10.1152/ajpendo.00201.2006. Epub 2006 Jul 5. PMID: 16822960.
8. Steiger A, Holsboer F. Neuropeptides and human sleep. Sleep. 1997 Nov;20(11):1038-52. PMID: 9456470.